HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Armkel update

This article was originally published in The Rose Sheet

Executive Summary

Nair depilatory and Arrid antiperspirant manufacturing move to Church & Dwight's Lakewood, N.J. facility from Carter-Wallace's Cranbury, N.J. location will be completed by second quarter, C&D Chief Financial Officer and Director of Armkel Integration Zvi Eiref says. C&D acquired Nair from Carter-Wallace in a 50/50 joint venture with Kelso in May and purchased C-W antiperspirant business in a second transaction (1"The Rose Sheet" May 14, 2001, p. 9). Move will result in 600 job cuts and severance costs of $15 mil., firm adds during April 4 analyst call. Financials for the JV from Sept. 28, when the acquisition was completed, through Dec. 31 were in line with preliminary reports issued in February, with revenues of $95.4 mil., and a net loss of $15.6 mil. (2"The Rose Sheet" Feb. 18, 2002, p. 9)...

You may also be interested in...

Nair Spa Kit, Wax Strip Extensions Aimed To Counter Share Declines

Nair depilatory line extensions en route to retailers include a Spa Kit, a higher-priced combination product to compete with recent premium-priced entries to the mass depilatory market, according to Church & Dwight

Church & Dwight U.S. Personal Care Sales Near $500 Mil. With C-W Brands

Church & Dwight's U.S. personal care product sales will increase more than three-fold to nearly $500 mil. with the acquisition of the Carter-Wallace consumer brands. Revenues for Church & Dwight's personal products business currently total about $150 mil., according to the company.

Indoco Aims To Leave Regulatory Woes Behind

India’s Indoco Remedies is looking for healthy revenue growth in the coming fiscal year after beating market estimates with a 70.4% year-on-year jump in after-tax profit in its financial third quarter, propelled by strong revenues from domestic and international markets.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts